NCT02252055 (ONEatDC) is a Phase 1, PHASE2 clinical trial of ATDC_Nantes in Renal Failure, End Stage, sponsored by Nantes University Hospital.

Who is sponsoring NCT02252055?

NCT02252055 is sponsored by Nantes University Hospital.

What drugs are being tested in NCT02252055?

Interventions in NCT02252055: ATDC_Nantes.

What condition does NCT02252055 study?

NCT02252055 studies Renal Failure, End Stage.

Is NCT02252055 still recruiting?

NCT02252055 is currently completed. Last updated 2 January 2019.

Last reviewed 2019-01-02 · How we verify

NCT02252055: ONEatDC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The ONE Study ATDC Trial

Completed Phase 1, PHASE2 Last updated 2 January 2019

What this trial tests

Phase 1, PHASE2 trial testing ATDC_Nantes in Renal Failure, End Stage in 11 participants. Completed in 14 November 2018.

Timeline

19 March 2015

Primary endpoint
14 November 2018

14 November 2018

Quick facts

Lead sponsor	Nantes University Hospital
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	19 March 2015
Primary completion	14 November 2018
Estimated completion	14 November 2018
Sites	1 location across France

Drugs / interventions tested

ATDC_Nantes — full drug profile →

Conditions studied

Renal Failure, End Stage — all drugs for Renal Failure, End Stage →

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Renal Failure, End Stage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To collect evidence of the safety of administering autologous tolerogenic dendritic cells (ATDC) preparations to living-donor renal transplant recipients in the context of an international European Union funded consortium aimed at evaluationg cellular immunotherapy in solid organ transplantation (The ONE Study). It is anticipated that immune regulation induced by ATDC therapy can evntually be used to reduce the need for conventional immunosuppression in transplant recipients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
Sawitzki B, Harden PN, Reinke P, Moreau A, et al · · 2020 · cited 341× · PMID 32446407 · DOI 10.1016/s0140-6736(20)30167-7
Therapeutic induction of antigen-specific immune tolerance.
Kenison JE, Stevens NA, Quintana FJ. · · 2024 · cited 94× · PMID 38086932 · DOI 10.1038/s41577-023-00970-x
Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation.
McDonald-Hyman C, Turka LA, Blazar BR. · · 2015 · cited 86× · PMID 25810312 · DOI 10.1126/scitranslmed.aaa6853
Tolerogenic Dendritic Cells in Solid Organ Transplantation: Where Do We Stand?
Marín E, Cuturi MC, Moreau A. · · 2018 · cited 79× · PMID 29520275 · DOI 10.3389/fimmu.2018.00274
Update on Dendritic Cell-Induced Immunological and Clinical Tolerance.
Obregon C, Kumar R, Pascual MA, Vassalli G, et al · · 2017 · cited 75× · PMID 29250057 · DOI 10.3389/fimmu.2017.01514
Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation.
Amodio G, Cichy J, Conde P, Matteoli G, et al · · 2019 · cited 60× · PMID 30357490 · DOI 10.1007/s00262-018-2264-3
Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.
Flórez-Grau G, Zubizarreta I, Cabezón R, Villoslada P, et al · · 2018 · cited 58× · PMID 29904379 · DOI 10.3389/fimmu.2018.01169
Regulatory dendritic cells for human organ transplantation.
Thomson AW, Metes DM, Ezzelarab MB, Raïch-Regué D. · · 2019 · cited 50× · PMID 31130302 · DOI 10.1016/j.trre.2019.05.001

Verify or expand the search:

Other Nantes University Hospital trials

Trials by the same sponsor.

NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02252055 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
Last refreshed: 2 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02252055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing